Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $9.00.

Aptose Biosciences Stock Up 1.3 %

Aptose Biosciences stock opened at $0.41 on Thursday. The stock has a market cap of $7.34 million, a PE ratio of -0.07 and a beta of 1.25. Aptose Biosciences has a 12-month low of $0.33 and a 12-month high of $3.32. The business’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.88.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.15. As a group, analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.